𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6–12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study

✍ Scribed by Agustin A. Garcia; John A. Blessing; Heinz-Josef Lenz; Kathleen M. Darcy; Robert S. Mannel; David Scott Miller; Nader Husseinzadeh

Book ID
113959709
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
132 KB
Volume
96
Category
Article
ISSN
0090-8258

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized phase III trial of tamoxifen
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study
✍ Jean A. Hurteau; Mark F. Brady; Kathleen M. Darcy; William P. McGuire; Pamela Ed 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 490 KB